2. Membrane Transporter/Ion Channel Neuronal Signaling Autophagy
  3. Calcium Channel Autophagy
  4. Dantrolene sodium hemiheptahydrate

Dantrolene sodium hemiheptahydrate  (Synonyms: Dantrolene sodium hydrate)

Cat. No.: HY-12542A Purity: 99.79%
SDS COA Handling Instructions

Molarity Calculator

Dantrolene sodium hemiheptahydrate is an orally active, non-competitive glutathione reductase inhibitor with a Ki of 111.6 μM and an IC50 of 52.3 μM. Dantrolene sodium hemiheptahydrate is a ryanodine receptor (RyR) antagonist and Ca2+ signaling stabilizer. Dantrolene sodium hemiheptahydrate is a direct-acting skeletal muscle relaxant. Dantrolene sodium hemiheptahydrate can be used for the research of muscle spasticity, malignant hyperthermia, Huntington's disease and other neuroleptic malignant syndrome.

For research use only. We do not sell to patients.

Dantrolene sodium hemiheptahydrate Chemical Structure

Dantrolene sodium hemiheptahydrate Chemical Structure

CAS No. : 24868-20-0

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 66 In-stock
Solution
10 mM * 1 mL in DMSO USD 66 In-stock
Solid
100 mg USD 60 In-stock
500 mg USD 180 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 8 publication(s) in Google Scholar

Other Forms of Dantrolene sodium hemiheptahydrate:

Dantrolene sodium hemiheptahydrate Related Antibodies

Top Publications Citing Use of Products

View All Calcium Channel Isoform Specific Products:

View All Isoforms
N-type calcium channel L-type calcium channel P/Q-type calcium channel T-type calcium channel Calcium Channel

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Dantrolene sodium hemiheptahydrate is an orally active, non-competitive glutathione reductase inhibitor with a Ki of 111.6 μM and an IC50 of 52.3 μM. Dantrolene sodium hemiheptahydrate is a ryanodine receptor (RyR) antagonist and Ca2+ signaling stabilizer. Dantrolene sodium hemiheptahydrate is a direct-acting skeletal muscle relaxant. Dantrolene sodium hemiheptahydrate can be used for the research of muscle spasticity, malignant hyperthermia, Huntington's disease and other neuroleptic malignant syndrome[1][2][3].

In Vitro

Dantrolene (60 μM; at 1 and 3 days) sodium hemiheptahydrate significantly inhibits ACTA2 expression and upregulats RUNX2 expression in paVICs[2].
Dantrolene (60 μM; overnight pretreatment) sodium hemiheptahydrate inhibits LPC-induced calcium flux in porcine aortic valve interstitial cells[2].
Dantrolene (10, 30, 60 μM) sodium hemiheptahydrate inhibits calcific nodule formation of paVICs due to 10 μM lysophosphatidylcholine (LPC)[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Dantrolene sodium hemiheptahydrate Related Antibodies

RT-PCR[2]

Cell Line: Porcine aortic valvular interstitial cells (paVICs)
Concentration: 60 μM
Incubation Time: At 1 and 3 days
Result: Significantly inhibited ACTA2 expression and upregulated RUNX2 expression.
In Vivo

Dantrolene (5 mg/kg; fed orally twice per week) sodium hemiheptahydrate improves performance in the beam-walking and gait-walking assay[3].
Dantrolene (10 mg/kg; IP; three days per week; for 40-60 days) sodium hemiheptahydrate significantly improves gait, reduces LC3-II levels, improves mitochondrial ATP production and reduced inflammation in the brain. Dantrolene sodium hemiheptahydrate partially reduces autophagy and the expression of CALM (calmodulin) in the brain of neuronopathic Gaucher disease mice[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: YAC128 transgenic mice (FVBN/NJ background strain) and WT mice[3]
Dosage: 5 mg/kg
Administration: Fed orally twice per week from 2 to 11.5 months of age
Result: Resulted in significantly improved performance in the beam-walking and gait-walking assays.
Significantly reduced the loss of NeuN-positive striatal neurons and reduced formation of Httexp nuclear aggregates.
Clinical Trial
Molecular Weight

399.31

Formula

C14H16N4NaO8.5
CAS No.
Appearance

Solid

Color

Yellow to orange

SMILES

O=C1N([Na])C(CN1/N=C/C2=CC=C(C3=CC=C([N+]([O-])=O)C=C3)O2)=O.[3.5H2O]
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility
In Vitro: 

DMSO : ≥ 33 mg/mL (82.64 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : < 0.1 mg/mL (insoluble)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.5043 mL 12.5216 mL 25.0432 mL
5 mM 0.5009 mL 2.5043 mL 5.0086 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 0.5 mg/mL (1.25 mM); Clear solution

    This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 0.5 mg/mL (1.25 mM); Clear solution

    This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.5043 mL 12.5216 mL 25.0432 mL 62.6080 mL
5 mM 0.5009 mL 2.5043 mL 5.0086 mL 12.5216 mL
10 mM 0.2504 mL 1.2522 mL 2.5043 mL 6.2608 mL
15 mM 0.1670 mL 0.8348 mL 1.6695 mL 4.1739 mL
20 mM 0.1252 mL 0.6261 mL 1.2522 mL 3.1304 mL
25 mM 0.1002 mL 0.5009 mL 1.0017 mL 2.5043 mL
30 mM 0.0835 mL 0.4174 mL 0.8348 mL 2.0869 mL
40 mM 0.0626 mL 0.3130 mL 0.6261 mL 1.5652 mL
50 mM 0.0501 mL 0.2504 mL 0.5009 mL 1.2522 mL
60 mM 0.0417 mL 0.2087 mL 0.4174 mL 1.0435 mL
80 mM 0.0313 mL 0.1565 mL 0.3130 mL 0.7826 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Dantrolene sodium hemiheptahydrate Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Dantrolene sodium hemiheptahydrate24868-20-0Dantrolene sodiumCalcium ChannelAutophagyCa2+ channelsCa channelsorallynon-competitiveglutathione reductaseryanodine receptorRyRCa2+muscle spasticitymalignant hyperthermiaHuntington's diseaseneuroleptic malignant syndromeInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Dantrolene sodium hemiheptahydrate
Cat. No.:
HY-12542A
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.